Article written by Jens Viktor Nørgaard
The new guidelines are here and there is cause for cautious optimism.
The new guidelines have been expected since early autumn and finally they were issued 16 December 2014. The guidelines are still open for debate and may be changed following public debate and feedback which will take place in January. At the same time there is also news from the US on Myriad Genetics’ attempt to enforce their method-claims against competitors who have started marketing BRCA1 tests following the Supreme Court’s decision that the claims directed to the isolated BRCA1 gene was invalid.